نتایج جستجو برای: hbv vaccine non

تعداد نتایج: 1426445  

2015
Reza Rezaee Bahman Aghcheli Vahdat Poortahmasebi Mostafa Qorbani Seyed Moayed Alavian Seyed Mohammad Jazayeri

CONTEXT Hepatitis B Virus expanded program on immunization (EPI) started on 1993 in Iran. Most surveys have assessed the level of response to vaccine by measuring the titers of anti-HBs. This meta- analysis aimed to summarize the Iranian published data on the rate of vaccine-responders versus non-responders. Moreover, the impact of variables such as age, gender, type of vaccine, etc. on the lev...

Journal: :Drug and alcohol dependence 2003
Karen H Seal Alex H Kral Jennifer Lorvick Alex McNees Lauren Gee Brian R Edlin

BACKGROUND Injection drug users (IDUs) are at high-risk for hepatitis B virus (HBV) and HIV. Due to concerns about non-adherence to multi-dose vaccine regimens however, IDUs are severely under-immunized against HBV and have been excluded from phase III trials of multi-dose candidate HIV vaccines in the United States. METHODS Through a randomized controlled trial, we compared the effectiveness...

Journal: :jundishapur journal of microbiology 0
roohangiz nashibi health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran seyed mohammad alavi health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran; health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran. tel: +98-6133387724, fax: +98-6133335396 farid yousefi health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran shokrolah salmanzadeh health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran sassan moogahi health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran fatemeh ahmadi health research institute, infectious and tropical diseases research center, ahvaz jundishapur university of medical sciences, ahvaz, ir iran

background hepatitis b virus (hbv) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (hcc). hb vaccination is an essential step in the prevention of the disease and its consequent complications. objectives immune status of medical personnel in teaching hospitals of khuzestan is not well known. since these personnel are usually at risk of needle stick and other...

Journal: :Journal of infection in developing countries 2016
Yiying Wang Lugang Yu Hui Zhou Zhiwei Zhou Huijuan Zhu Yinghui Li Zhi Zheng Xinxin Li Chen Dong

INTRODUCTION Previous studies have indicated that the patients with psychiatric illness were at higher risk of hepatitis B virus (HBV) infection. However, the efficacy of hepatitis B vaccine in schizophrenia patients remains unclear. METHODOLOGY Between June 2014 and January 2015, 415 schizophrenia patients and 3,038 controls who had been routinely immunized as infants were recruited in the p...

Journal: :Ghana medical journal 2017
Thomas Apiung Thomas A Ndanu Julius Aa Mingle Kwamena Wc Sagoe

OBJECTIVES The knowledge about outcomes of infant vaccination against HBV infections using the DPT-HepB-Hib vaccine in Ghana is limited. This study therefore investigated the levels of immunity to HBV among children who received the DPT-HepB-Hib vaccine and HBsAg carriage in non-responders. Correlates for non-response or poor response were also investigated. METHODS Cross-sectional study. A m...

2011
Edgar T Overton Somnuek Sungkanuparph Michael Klebert Michael Royal Debra Demarco-Shaw William G Powderly Judith A Aberg

BACKGROUND Hepatitis B (HBV) vaccination is an important preventive intervention for HIV-infected population. Data regarding booster HBV vaccine for persons with low HBV surface antibody (sAb) titers after vaccination in this immunocompromised population is lacking. METHODS We randomized 60 HIV-infected subjects lacking HBV protection after completion of 3 doses of HBV vaccine to receive a bo...

2012
Hong Chen Xia Chuai Yao Deng Bo Wen Wen Wang Shaoqing Xiong Li Ruan Wenjie Tan

BACKGROUND A therapeutic vaccine for chronic hepatitis B virus (HBV) infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development. METHODOLOGY/PRINCIPAL FINDINGS To develop an...

2017
Fu-Qiang Yang Gui-Rong Rao Gui-Qiang Wang Yue-Qi Li Yao Xie Zhan-Qing Zhang Cun-Liang Deng Qing Mao Jun Li Wei Zhao Mao-Rong Wang Tao Han Shi-Jun Chen Chen Pan De-Ming Tan Jia Shang Ming-Xiang Zhang Yue-Xin Zhang Ji-Ming Yang Guang-Ming Chen

AIM To assess the efficacy and safety of in vivo electroporation (EP)-mediated dual-plasmid hepatitis B virus (HBV) DNA vaccine vs placebo for sequential combination therapy with lamivudine (LAM) in patients with chronic hepatitis B. METHODS Two hundred and twenty-five patients were randomized to receive either LAM + vaccine (vaccine group, n = 109) or LAM + placebo (control group, n = 116). ...

Journal: :international journal of preventive medicine 0
mohammad minakari afshin tahmasebi mahyar hosseini motlagh behrooz ataei majid yaran hamid kalantari

background: hepatitis b virus (hbv) vaccination is a well-known, safe and effective way for protection against hbv infection; however, non-responders remain susceptible to infection with hbv. this is so important in patients with any kind of chronic liver disease, especially chronic hepatitis c virus (hcv) patients in whom acute hbv infection may lead to decompensation of liver disease. some of...

2010
Sukanta Chatterjee Sylvan J Rego Fulton D'Souza BD Bhatia Alix Collard Sanjoy K Datta Jeanne-Marie Jacquet

BACKGROUND Combination vaccines improve coverage, compliance and effectively introduce new antigens to mass vaccination programmes. This was a phase III, observer-blind, randomized study of GSK Biologicals diphtheria-tetanus-whole cell pertussis vaccine combined with hepatitis B and Haemophilus influenzae type b vaccines, containing a reduced amount of polyribosyl-ribitol-phosphate (PRP) and a ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید